

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



DEA

(PC

(51) Classification internationale des brevets ⁶ :
 C12N 15/86, 15/34, 5/10, 7/04, C07K
 14/075 A1
 (11) Numéro de publication internationale: WO 95/0269
 (43) Date de publication internationale: 26 janvier 1995 (26.01.95)

(21) Numéro de la demande internationale: PCT/FR94/00851

(22) Date de dépôt international: 8 juillet 1994 (08.07.94)

(30) Données relatives à la priorité:
 93/08596 13 juillet 1993 (13.07.93) FR
 94/14590 18 avril 1994 (18.04.94) FR

(71) Déposant (pour tous les Etats désignés sauf US): RHONE-POULENC RORER S.A. [FR/FR]; 20, avenue Raymond-Aron, F-92160 Antony (FR).

(72) Inventeurs; et

(75) Inventeurs/Déposants (US seulement): PERRICAUDET, Michel [FR/FR]; 31, rue de Chartres, F-28320 Ecrosnes (FR). VIGNE, Emmanuelle [FR/FR]; 60, rue Jean-le-Galleu, F-94200 Ivry-sur-Seine (FR). YEH, Patrice [FR/FR]; 11 bis, rue Lapepère, F-75005 Paris (FR).

(74) Mandataire: BECKER, Philippe; Rhône-Poulenc Rorer S.A., Direction Brevets, 20, avenue Raymond-Aron, F-92165 Antony Cédex (FR).

(81) Etats désignés: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, brevet européen (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Publiée

Avec rapport de recherche internationale.

(54) Title: DEFECTIVE ADENOVIRUS VECTORS AND USE THEREOF IN GENE THERAPY


(54) Titre: VECTEURS ADENOVIRAUX DEFECTIFS ET UTILISATION EN THERAPIE GENIQUE

(57) Abstract

Novel adenovirus-derived viral vectors, the preparation thereof, and the use thereof in gene therapy, are disclosed.


(57) Abrégé

La présente invention concerne de nouveaux vecteurs viraux dérivés des adénovirus, leur préparation et leur utilisation en thérapie génique.



X


H201808



IN THE MATTER OF an Australian
Application corresponding to
PCT Application PCT/FR94/00851

I, Abraham SMITH DipIng DipDoc,
c/o Europa House, Marsham Way, Gerrards Cross, Buckinghamshire,
England, do solemnly and sincerely declare that I am conversant
with the English and French languages and am a competent
translator thereof, and that to the best of my knowledge and
belief the following is a true and correct translation of the
PCT Application filed under No. PCT/FR94/00851.

Date: 1 March 1995

A handwritten signature in cursive script, appearing to read 'Abraham Smith', written in dark ink.

A. SMITH

For and on behalf of RWS Translations Ltd.

PCT WORLD ORGANISATION FOR INTELLECTUAL PROPERTY
International Office
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT
COOPERATION TREATY (PCT)

<p>(51) International patent classification: C12N 15/86, 15/34, 5/10, 7/04, C07K 14/075</p>	<p>A1</p>	<p>(11) International publication number: WO 95/02697 (43) International publication date: 26 January 1995 (26.01.95)</p>
<p>(21) International application number: PCT/FR94/00851</p> <p>(22) International filing date: 8 July 1994 (08.07.94)</p> <p>(30) Data relating to the priority: 93/08596 13 July 1993 (13.07.93) FR 94/04590 18 April 1994 (18.04.94) FR</p> <p>(71) Applicant (for all designated States except US): RHONE-POULENC RORER S.A. [FR/FR]: 20, avenue Raymond-Aron, F-92160 Antony (FR).</p> <p>(72) Inventors: and (75) Inventors/Applicants (US only): Michel PERRICAUDET [FR/FR]: 31, rue de Chartres, F-28320 Ecrosnes (FR). Emmanuelle VIGNE [FR/FR]: 60, rue Jean-le-Galleu, F-94200 Ivry-sur-Seine (FR). Patrice YEH [FR/FR]: 11 bis, rue Lapepède, F-75005 Paris (FR).</p> <p>(74) Representative: Philippe BECKER: Rhône-Poulenc Rorer S.A., Patents Directorate, 20, avenue Raymond-Aron, F-92165 Antony Cédex (FR).</p>		<p>(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European Patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published: With the International Search Report.</p>

As printed

(54) Title: DEFECTIVE ADENOVIRUS VECTORS AND USE THEREOF IN GENE THERAPY

(54) Titre: VECTEURS ADENOVIRAUX DEFECTIFS ET UTILISATION EN THERAPIE GENIQUE

(57) Abstract


Novel adenovirus-derived viral vectors, the preparation thereof, and the use thereof in gene therapy, are disclosed.

(57) Abrégé

La présente invention concerne de nouveaux vecteurs viraux dérivés des adénovirus, leur préparation et leur utilisation en thérapie génique.



X
HindIII



ONLY FOR INFORMATION

Codes used to identify the PCT member States on the flyleaves of the brochures in which international applications made under the PCT are published.

AT	Austria	KR	Republic of Korea
AU	Australia	KZ	Kazakhstan
BB	Barbados	LI	Liechtenstein
BE	Belgium	LK	Sri Lanka
BF	Burkina Fasso	LU	Luxembourg
BG	Bulgaria	LV	Latvia
BJ	Benin	MC	Monaco
BR	Brazil	MD	Republic of Moldova
BY	Belarus	MG	Madagascar
CA	Canada	ML	Mali
CF	Central African Republic	MN	Mongolia
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CI	Ivory Coast	NE	Niger
CM	Cameroon	NL	Netherlands
CN	China	NO	Norway
CS	Czechoslovakia	NZ	New Zealand
CZ	Czech Republic	PL	Poland
DE	Germany	PT	Portugal
DK	Denmark	RO	Rumania
ES	Spain	RU	Russian Federation
FI	Finland	SD	Sudan
FR	France	SE	Sweden
GA	Gabon	SI	Slovenia
GB	United Kingdom	SK	Slovakia
GE	Georgia	SN	Senegal
GN	Guinea	TD	Chad
GR	Greece	TG	Togo
HU	Hungary	TJ	Tadjikistan
IE	Ireland	TT	Trinidad and Tobago
IT	Italy	UA	Ukraine
JP	Japan	US	United States of America
KE	Kenya	UZ	Uzbekhistan
KG	Kirghizistan	VN	Vietnam
KP	Democratic People's Republic of Korea		

DEFECTIVE ADENOVIRAL VECTORS AND USE IN GENE THERAPY

The present invention relates to new viral vectors, their preparation and their use in gene therapy. It also relates to the pharmaceutical compositions containing the said viral vectors. More particularly, the present invention relates to recombinant adenoviruses as vectors for gene therapy.

Gene therapy consists in correcting a deficiency or an abnormality (mutation, aberrant expression and the like) by the introduction of a genetic information into the cell or affected organ. This genetic information can be introduced either in vitro or in a cell extracted from the organ, the modified cell then being reintroduced into the body, or directly in vivo into the appropriate tissue. In this second case, various techniques exist, among which various transfection techniques involving complexes of DNA and DEAE-dextran (Pagano et al., J. Virol. 1 (1967) 891), of DNA and nuclear proteins (Kaneda et al., Science 243 (1989) 375), of DNA and lipids (Felgner et al., PNAS 84 (1987) 7413), the use of liposomes (Fraley et al., J. Biol. Chem. 255 (1980) 10431) and the like. More recently, the use of viruses as vectors for the transfer of genes has appeared as a promising alternative to these physical transfection techniques. In this respect, various viruses have been tested for their capacity to infect certain cellular populations. In particular, the retroviruses (RSV, HMS, MMS and the

like), the HSV virus, the adeno-associated viruses and the adenoviruses.

Among these viruses, adenoviruses present some advantageous properties for a use in gene therapy. Especially, they have a fairly broad host spectrum, are capable of infecting quiescent cells, do not integrate into the genome of the infected cell, and have not been associated to date with major pathologies in man.

Adenoviruses are viruses with linear double-stranded DNA of a size of about 36 kb. Their genome comprises especially an inverted repeat sequence (ITR) at their end, an encapsulation sequence, early genes and late genes (cf Figure 1). The principal early genes are the E1 (E1a and E1b), E2, E3 and E4 genes. The principal late genes are the L1 to L5 genes.

Given the properties of the abovementioned adenoviruses, the latter have already been used for the transfer of genes in vivo. To this end, various vectors derived from adenoviruses have been prepared, incorporating various genes (β -gal, OTC, α -LAT, cytokines and the like). In each of these constructs, the adenovirus was modified so as to render it incapable of replication in the infected cell. Thus, the constructs described in the prior art are adenoviruses from which there have been deleted the E1 (E1a and/or E1b) and optionally E3 regions at the level of which the heterologous DNA sequences are inserted (Levrero et al., Gene 101 (1991) 195; Gosh-Choudhury et

al., Gene 50 (1986) 161). Nevertheless, the vectors described in the prior art have numerous disadvantages which limit their exploitation in gene therapy. In particular, all these vectors contain numerous viral
5 genes whose expression in vivo is not desirable within the framework of a gene therapy. Furthermore, these vectors do not permit the incorporation of very large DNA fragments which may be necessary for certain applications.

10 The present invention makes it possible to overcome these disadvantages. The present invention indeed describes recombinant adenoviruses for gene therapy, which are capable of efficiently transferring DNA (up to 30 kb) in vivo, of expressing at high levels
15 and in a stable manner this DNA in vivo, while limiting any risk of production of viral proteins, of transmission of the virus, of pathogenicity and the like. In particular, it was found that it is possible to considerably reduce the size of the adenovirus gene
20 without preventing the formation of an encapsulated viral particle. This is surprising since it had been observed in the case of other viruses, for example retroviruses, that certain sequences distributed along the genome where necessary for an efficient
25 encapsulation of the viral particles. Because of these, the production of vectors possessing substantial internal deletions was highly limited. The present invention also shows that neither does the suppression

of most of the viral genes prevent the formation of such a viral particle. Furthermore, the recombinant adenoviruses thus obtained preserve, in spite of the substantial modifications of their genomic structure, their advantageous properties of high infectivity, of stability in vivo and the like.

The vectors of the invention are particularly advantageous since they permit the incorporation of desired DNA sequences of very large size. It is thus possible to insert a gene of a length greater than 30 kb. This is particularly advantageous for some pathologies whose treatment requires the co-expression of several genes, or the expression of very large genes. Thus, for example, in the case of muscular dystrophy, it was not until now possible to transfer the cDNA corresponding to the native gene responsible for this pathology (dystrophin gene) because of its large size (14 kb).

The vectors of the invention are also very advantageous since they possess very few functional viral regions and since, because of this, the risks inherent in the use of viruses as vectors in gene therapy such as immunogenicity, pathogenicity, transmission, application, recombination and the like, are substantially reduced or even suppressed.

The present invention thus provides viral vectors which are particularly adapted to the transfer and expression in vivo of desired DNA sequences.

A first subject of the present invention therefore relates to a defective recombinant adenovirus comprising:

- ITR sequences,
- a sequence permitting the encapsulation,
- a heterologous DNA sequence,

and in which:

- the E1 gene is non-functional and
 - at least one of the E2, E4 and L1-L5 genes
- is non-functional.

For the purposes of the present invention, the term "defective adenovirus" designates an adenovirus incapable of replicating autonomously in the target cell. Generally, the genome of the defective adenoviruses according to the present invention is therefore devoid of at least the sequences necessary for the replication of the said virus in the infected cell. These regions can be either removed (completely or partly), or rendered non-functional, or substituted by other sequences and especially by the heterologous DNA sequence.

The inverted repeat sequences (ITR) constitute the replication origin of the adenoviruses. They are localized at the 3' and 5' ends of the viral genome (cf Figure 1), from where they can be easily isolated according to conventional molecular biology techniques known to persons skilled in the art. The nucleotide sequence of the ITR sequences of human

adenoviruses (in particular of the Ad2 and Ad5 serotypes) is described in the literature, as well as of canine adenoviruses (especially CAV1 and CAV2). As regards the Ad5 adenovirus for example, the left ITR
5 sequence corresponds to the region comprising nucleotides 1 to 103 of the genome.

The encapsulation sequence (also designated Psi sequence) is necessary for the encapsulation of the viral DNA. This region should therefore be present in
10 order to permit the preparation of defective recombinant adenoviruses according to the invention. The encapsulation sequence is localized in the genome of adenoviruses, between the left (5') ITTR and the E1 gene (cf Figure 1). It can be isolated or synthesized
15 artificially by conventional molecular biology techniques. The nucleotide sequence of the encapsulation sequence of human adenoviruses (in particular of the Ad2 and Ad5 serotypes) is described in the literature, as well as of canine adenoviruses
20 (especially CAV1 and CAV2). As regards the Ad5 adenovirus for example, the encapsulation sequence corresponds to the region comprising nucleotides 194 to 358 of the genome.

There are various adenovirus serotypes whose
25 structure and properties vary somewhat. Nevertheless, these viruses exhibit a comparable genetic organization, and the information described in the present application can be easily reproduced by

persons skilled in the art for any type of adenovirus.

The adenoviruses of the invention may be of human, animal or mixed (human and animal) origin.

As regards the adenoviruses of human origin,
5 the use of those classified in group C is preferred.
More preferably, among the various human adenovirus serotypes, the use of the type 2 or 5 adenoviruses (Ad2 or Ad5) is preferred within the framework of the present invention.

10 As indicated above, the adenoviruses of the invention may also be of animal origin, or contain sequences derived from adenoviruses of animal origin. The Applicant has indeed shown that the adenoviruses of animal origin are capable of infecting, with a high
15 efficiency, human cells, and that they are incapable of propagating in the human cells in which they were tested (cf Application FR 93 05954). The Applicant also showed that the adenoviruses of animal origin are not at all transcomplemented by adenoviruses of human
20 origin, which eliminates any risk of recombination and of propagation in vivo, in the presence of a human adenovirus, capable of leading to the formation of infectious particles. The use of adenoviruses or of adenovirus regions of animal origin is therefore
25 particularly advantageous since the risks inherent in the use of viruses as vectors in gene therapy are even smaller.

The adenoviruses of animal origin which can

be used within the framework of the present invention may be of canine, bovine, murine, (example: Mavl, Beard et al., Virology 75 (1990) 81), ovine, porcine or avian or alternatively simian origin (example: SAV). More particularly, among the avian adenoviruses, there may be mentioned the serotypes 1 to 10 which are available at ATCC, such as for example the strains Phelps (ATCC VR-432), Fontes (ATCC VR-280), P7-A (ATCC VR-827), IBH-2A (ATCC VR-828), J2-A (ATCC VR-829), T8-A (ATCC VR-830), K-11 (ATCC VR-921) or alternatively the strains referenced ATCC VR-831 to 835. Among the bovine adenoviruses, the various known serotypes can be used, and especially those available at ATCC (types 1 to 8) under the references ATCC VR-313, 314, 639-642, 768 and 769. There may also be mentioned the murine adenoviruses FL (ATCC VR-550) and E20308 (ATCC VR-528), the type 5 (ATCC VR-1343), or type 6 (ATCC VR-1340) ovine adenovirus; the porcine adenovirus 5359), or the simian adenoviruses such as especially the adenoviruses referenced at ATCC under the numbers VR-591-594, 941-943, 195-203 and the like.

Preferably, among the various adenoviruses of animal origin, adenoviruses or adenovirus regions of canine origin, and especially all the CAV2 adenovirus strains [manhattan or A26/61 strain (ATCC VR-800) for example] are used within the framework of the invention. The canine adenoviruses have been the subject of numerous structural studies. Thus, complete

restriction maps of the CAV1 and CAV2 adenoviruses have been described in the prior art (Spibey et al., J. Gen. Virol, 70 (1989) 165), and the E1a and E3 genes as well as the ITR sequences have been cloned and sequenced
5 (see especially Spibey et al., Virus Res. 14 (1989) 241; Linné, Virus Res. 23 (1992) 119, WO 91/11525).

As indicated above, the adenoviruses of the present invention contain a heterologous DNA sequence. The heterologous DNA sequence designates any DNA
10 sequence introduced into the recombinant virus, whose transfer and/or expression in the target cell is desired.

In particular, the heterologous DNA sequence may contain one or more therapeutic genes and/or one or
15 more genes encoding antigenic peptides.

The therapeutic genes which can thus be transferred are any gene whose transcription and optionally translation in the target cell generates products having a therapeutic effect.

20 This may be in particular genes encoding protein products having a therapeutic effect. The protein product thus encoded may be a protein, a peptide, an amino acid and the like. This protein product may be homologous with respect to the target
25 cell (that is to say a product which is normally expressed in the target cell when the latter presents no pathology). In this case, the expression of a protein makes it possible for example to palliate an

insufficient expression in the cell or the expression of an inactive or weakly active protein as a result of a modification, or alternatively to overexpress the said protein. The therapeutic gene may also encode a
5 mutant of a cellular protein, having an increased stability, a modified activity and the like. The protein product may also be heterologous with respect to the target cell. In this case, an expressed protein can for example supplement or provide an activity
10 deficient in the cell which enables it to combat a pathology.

Among the therapeutic products for the purposes of the present invention, there may be mentioned more particularly enzymes, blood derivatives,
15 hormones, lymphokines: interleukins, interferons, TNF, and the like (FR 9203120), growth factors, neurotransmitters or their precursors or synthetic enzymes, trophic factors: BDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3, NT5 and the like; apolipoproteins:
20 ApoAI, ApoAIV, ApoE and the like (FR 93 05125), dystrophin or minidystrophin (FR 9111947), tumour suppressor genes: p53, Rb, RplA, DCC, k-rev and the like (FR 93 04745), the genes encoding factors involved in coagulation: Factors VII, VIII, IX and the like.

25 The therapeutic gene can also be an antisense gene or sequence, whose expression in the target cell makes it possible to control the expression of genes or the description of cellular mRNAs. Such sequences can

for example be transcribed, in the target cell, into RNAs which are complementary to cellular mRNAs and thus block their translation into protein, according to the technique described in Patent EP 140 308.

5 As indicated above, the heterologous DNA sequence may also contain one or more genes encoding an antigenic peptide, capable of generating an immune response in man. In this particular implementational embodiment, the invention therefore permits the
10 production of vaccines which make it possible to immunize man, especially against microorganisms or viruses. These may be especially antigenic peptides specific for the Epstein Barr virus, the HIV virus, the hepatitis B virus (EP 185 573), the pseudo-rabies
15 virus, or alternatively specific for tumours (EP 259 212).

 Generally, the heterologous DNA sequence also comprises sequences permitting the expression of the therapeutic gene and/or of the gene encoding the
20 antigenic peptide in the infected cell. There may be sequences which are naturally responsible for the expression of the considered gene when these sequences are capable of functioning in the infected cell. They may also be sequences of different origin (responsible
25 for the expression of other proteins, or even synthetic). In particular, they may be promotor sequences of eucaryotic or viral genes. For example, they may be promotor sequences derived from the genome

of the cell which it is desired to infect. Likewise, they may be promotor sequences derived from the genome of a virus, including the adenovirus used. In this respect, there may be mentioned for example the
5 promoters of the E1A, MLP, CMV and RSV genes and the like. In addition, these expression sequences can be modified by addition of activating sequences, regulatory sequences and the like. Moreover, when the inserted gene does not contain expression sequences it
10 can be inserted into the genome of the defective virus downstream of such a sequence.

Furthermore, the heterologus DNA sequence may also contain, in particular upstream of the therapeutic gene, a signal sequence directing the therapeutic
15 product synthesized in the secretory pathways of the target cell. This signal sequence may be the natural signal sequence of the therapeutic product, but it may also be any other functional signal sequence, or an artificial signal sequence.

20 As indicated above, the vectors of the invention possess at least one of the non-functional E2, E4 and L1-L5 genes. The viral gene considered can be rendered non-functional by any technique known to a person skilled in the art, and especially by
25 supression, substitution deletion or addition of one or more bases in the gene(s) considered. Such modifications can be obtained in vitro (on the isolated DNA) cr in situ, for example, by means of genetic

engineering techniques, or alternatively by treating with mutagenic agents.

Among the mutagenic agents, there may be mentioned for example physical agents such as energetic
5 radiations (X-, γ - and ultraviolet rays and the like), or chemical agents capable of reacting with various functional groups of the bases of the DNA, and for example alkylating agents [ethyl methanesulphonate (EMS), N-methyl-N'-nitro-N-nitrosoguanidine, N-
10 nitroquinoline-1-oxide (NQO)], bialkylating agents, intercalating agents and the like.

By deletion, there is understood for the purposes of the invention, any suppression of the gene considered. This may be especially all or part of the
15 coding region of the said gene, and/or all or part of the promotor region for transcription of the said gene. The suppression can be carried out by digestion by means of appropriate restriction enzymes, and then ligation, according to conventional molecular biology
20 techniques, as illustrated in the examples.

The genetic modifications can also be obtained by gene disruption, for example according to the procedure initially described by Rothstein [Meth. Enzymol. 101 (1983) 202]. In this case, all or part of
25 the coding sequence is preferably perturbed so as to permit the replacement, by homologous recombination, of the genomic sequence by a non-functional or mutant sequence.

The said genetic modification(s) may be localized in the coding part of the relevant gene, or outside the coding region, and for example in the regions responsible for the expression and/or

5 transcriptional regulation of the said genes. The non-functional character of the said genes can therefore manifest itself by the production of an inactive protein because of structural or conformational modifications, by the absence of production, by the

10 production of a protein having an altered activity, or alternatively by the production of the natural protein at an attenuated level or according to a desired mode of regulation.

Moreover, some alterations such as point

15 mutations are, by nature, capable of being corrected or attenuated by cellular mechanisms. Such genetic alterations are then of a limited interest at the industrial level. It is therefore particularly preferred that the non-functional character is

20 perfectly stable segregationally and/or non-reversible.

Preferably, the gene is non-functional because of a partial or total deletion.

Preferably, the defective recombinant adenoviruses of the invention are devoid of adenovirus

25 late genes.

A particularly advantageous embodiment of the invention consists in a defective recombinant adenovirus comprising:

- the ITR sequences,
 - a sequence permitting the encapsulation,
 - a heterologous DNA sequence, and
 - a region carrying the gene or a part of the
- 5 gene E2.

Another particularly advantageous embodiment of the invention consists in a defective recombinant adenovirus comprising:

- the ITR sequences,
 - a sequence permitting the encapsulation,
 - a heterologous DNA sequence, and
 - a region carrying the gene or a part of the
- 10 gene E4.

Still in a particularly advantageous
15 embodiment, the vectors of the invention possess, in addition, a functional gene E3 under the control of a heterologous promotor. More preferably, the vectors possess part of the E3 gene permitting the expression of the protein gp19K.

20 The defective recombinant adenoviruses according to the invention can be prepared in various ways.

A first method consists in transfecting the DNA from the defective recombinant virus prepared in
25 vitro (either by ligation, or in plasmid form) into a competent cell line, that is to say carrying in trans all the functions necessary for the complementation of the defective virus. These functions are preferably

integrated in the genome of the cell, which makes it possible to avoid the risks of recombination, and confers increased stability on the cell line. The preparation of such cell lines is described in the
5 examples.

A second approach consists in co-transfecting, into an appropriate cell line, the DNA from the defective recombinant virus prepared in vitro (either by ligation, or in plasmid form) and the DNA
10 from a helper virus. According to this method, it is not necessary to have a competent cell line capable of complementing all the defective functions of the recombinant adenovirus. Part of these functions is indeed complemented by the helper virus. This helper
15 virus should itself be defective and the cell line carries in trans the functions necessary for its complementation. The preparation of defective recombinant adenoviruses of the invention according to this method is also illustrated in the examples.

20 Among the cell lines which can be used within the framework of this second approach, there may be mentioned especially the human embryonic kidney line 293, the KB cells, the Hela, MDCK and GHK cells and the like (cf examples).

25 Then the vectors which have multiplied are recovered, purified and amplified according to conventional molecular biology techniques.

The present invention therefore also relates

to the cell lines which can be infected by adenoviruses, comprising, integrated in their genome, the functions necessary for the complementation of a defective recombinant adenovirus as described above. In particular, it relates to the cell lines containing, integrated in their genome, the regions E1 and E2 (especially the region encoding the 72K protein) and/or E4 and/or the gene for the glucocorticoid receptor. Preferably, these lines are obtained from the 293 or gm DBP6 line.

The present invention also relates to any pharmaceutical composition comprising one or more defective recombinant adenoviruses as described above. The pharmaceutical compositions of the invention can be formulated for a topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular and transdermal administration and the like.

Preferably, the pharmaceutical composition contains vehicles which are pharmaceutically acceptable for an injectable formulation. These may be in particular saline (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), sterile or isotonic solutions, or dry, especially freeze-dried, compositions, which by addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.

The virus doses used for the injection can be

adapted as a function of various parameters, and especially as a function of the mode of administration used, the relevant pathology, the gene to be expressed, or alternatively the desired duration of the treatment.

5 Generally, the recombinant adenoviruses according to the invention are formulated and administered in the form of doses of between 10^4 and 10^{14} pfu/ml, and preferably 10^6 to 10^{10} pfu/ml. The term pfu ("plaque forming unit") corresponds to the infectivity of a
10 virus solution, and is determined by infecting an appropriate cell culture, and measuring, generally after 5 days, the number of plaques of infected cells. The techniques for the determination of the pfu titre of a viral solution are well documented in the
15 literature.

Depending on the inserted heterologous DNA sequence, the adenoviruses of the invention can be used for the treatment or prevention of numerous pathologies including genetic diseases (dystrophy, cystic fibrosis
20 and the like), neurodegenerative diseases (Alzheimer, Parkinson, ALS and the like), cancers, pathologies linked to coagulation disorders and to dyslipoproteinaemias, pathologies linked to viral infections (hepatitis, AIDS and the like) and the like.

25 The present invention will be more fully described with the aid of the following examples which should be considered as illustrative and non-limiting.

Legend to the figures

Figure 1: Genetic organization of the Ad5 adenovirus. The complete sequence of Ad5 is available on database and enables persons skilled in the art to select or
5 create any restriction site, and thus to isolate any region of the genome.

Figure 2: Restriction map of the CAV2 adenovirus Manhattan strain (according to Spibey et al., previously cited).

10 Figure 3: Construction of defective viruses of the invention by ligation.

Figure 4: Construction of a recombinant virus carrying the E4 gene.

15 Figure 5: Construction of a recombinant virus carrying the E2 gene.

Figure 6: Construction and representation of the plasmid pPY32.

Figure 7: Representation of the plasmid pPY55.

Figure 8: Representation of the plasmid p2.

20 Figure 9: Representation of the intermediate plasmid used for the construction of the plasmid pITRL5-E4.

Figure 10: Representation of the plasmid pITRL5-E4.

General molecular biology techniques

The conventional methods used in molecular
25 biology such as preparative extractions of plasmid DNA, centrifugation of plasmid DNA in cesium chloride gradient, electrophoresis on agarose or acrylamide gels, purification of DNA fragments by electroelution,

protein extractions with phenol or phenol-chloroform, DNA precipitation in saline medium with ethanol or isopropanol, transformation in *Escherichia coli* and the like, are well known to persons skilled in the art and
5 are widely described in the literature [Maniatis T. et al., "Molecular Cloning, a Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982; Ausubel F.M. et al. (eds), "Current Protocols in Molecular Biology", John Wiley & Sons, New York, 1987].

10 The pBR322 and pUC type plasmids and the phages of the M13 series are of commercial origin (Bethesda Research Laboratories).

For the ligations, the DNA fragments can be separated according to their size by agarose or
15 acrylamide gel electrophoresis, extracted with phenol or with a phenol/chloroform mixture, precipitated with ethanol and then incubated in the presence of phage T4 DNA ligase (Biolabs) according to the recommendations of the supplier.

20 The filling of the protruding 5' ends can be performed with the Klenow fragment of DNA polymerase I of *E. coli* (Biolabs) according to the specifications of the supplier. The destruction of the protruding 3' ends is performed in the presence of phage T4 DNA polymerase
25 (Biolabs) which is used according to the recommendations of the manufacturer. The destruction of the protruding 5' ends is performed by a controlled treatment with S1 nuclease.

The site-directed mutagenesis in vitro with synthetic oligodeoxynucleotides can be carried out according to the method developed by Taylor et al. [Nucleic Acids Res. 13 (1985) 8749-8764] using the kit distributed by Amersham.

The enzymatic amplification of DNA fragments by the so-called PCR technique [Polymérase-catalyzed Chain Reaction, Saiki R.K. et al., Science 230 (1985) 1350-1354; Mullis K.B. and Faloona F.A., Meth. Enzym. 155 (1987) 335-350] can be carried out using the "DNA thermal cycler" (Perkin Elmer Cetus) according to the specifications of the manufacturer.

The verification of the nucleotide sequences can be carried out by the method developed by Sanger et al. [Proc. Natl. Acad. Sci. USA, 74 (1977) 5463-5467] using the kit distributed by Amersham.

Cell lines used

In the following examples, the following cell lines were or can be used:

- Human embryonic kidney line 293 (Graham et al., J. Gen. Virol. 36 (1977) 59). This line contains especially, integrated in its genome, the left part of the genome of the human adenovirus Ad5 (12%).

- Human cell line KB: derived from a human epidermal carcinoma, this line is available at ATCC (ref. CCL17) as well as the conditions permitting its culture.

- Human cell line Hela: derived from a

carcinoma of the human epichelium, this line is available at ATCC (ref. CCL2) as well as the conditions permitting its culture.

- Canine cell line MDCK: the conditions for culture of the MDCK cells have been described especially by Macatney et al., Science 44 (1988)9.

- Cell line gm DBP6 (Brough et al., Virology 190 (1992) 624). This line consists of Hela cells carrying the adenovirus E2 gene under the control of the LTR of MMTV.

EXAMPLES

Example 1

This example demonstrates the feasibility of a recombinant adenovirus devoid of most of the viral genes. For that, a series of adenovirus deletion mutants was constructed by ligation in vitro, and each of these mutants was co-transfected with a helper virus into the KB cells. These cells not permitting the propagation of the viruses defective for E1, the transcomplementation applies to the E1 region.

The various deletion mutants were prepared from the Ad5 adenovirus by digestion and then ligation in vitro. For that, the viral DNA from Ad5 is isolated according to the technique described by Lipp et al. (J. Virol. 63 (1989) 5133), subjected to digestion in the presence of various restriction enzymes (cf Figure 3), and then the digestion product is ligated in the presence of T4 DNA ligase. The size of the various

deletion mutants is then checked on a 0.8% SDS-agarose gel. These mutants are then mapped (cf Figure 3). These various mutants contain the following regions:

- mt1: Ligation between the Ad5 fragments 0-20642 (SauI) and (SauI)33797-35935
- mt2: Ligation between the Ad5 fragments 0-19549 (NdeI) and (NdeI)31089-35935
- mt3: Ligation between the Ad5 fragments 0-10754 (AatII) and (AatII)25915-35935
- mt4: Ligation between the Ad5 fragments 0-11311 (MluI) and (MluI)24392-35935
- mt5: Ligation between the Ad5 fragments 0-9462 (SalI) and (XhoI)29791-35935
- mt6: Ligation between the Ad5 fragments 0-5788 (XhoI) and (XhoI)29791-35935
- mt7: Ligation between the Ad5 fragments 0-3665 (SphI) and (SphI)31224-35935

Each of the mutants prepared above was co-transfected with the viral DNA from Ad.RSV β Gal (Stratford-Perricaudet et al., J. Clin. Invest. 90 (1992) 626) into the KB cells, in the presence of calcium phosphate. The cells were harvested 8 days after the transfection, and the culture supernatants were harvested and then amplified on KB cells until stocks of 50 dishes were obtained for each transfection. From each sample, episomal DNA was isolated and separated on cesium chloride gradient. Two distinct virus bands were observed in each case,

collected and analysed. The heavier corresponds to the viral DNA from Ad.RSV β Gal, and the lighter to the DNA from the recombinant virus generated by ligation (Figure 3). The titre obtained for the latter is about 5 10⁶ pfu/ml.

A second series of adenovirus deletion mutants was constructed by ligation in vitro according to the same methodology. These various mutants contain the following regions:

10 mt8:Ligation between the fragments 0-4623(ApaI) from Ad RSV β Gal and (ApaI)31909-35935 from Ad5.

mt9:Ligation between the fragments 0-10178(BglIII) from Ad RSV β Gal and (BamHI)21562-35935 from Ad5.

These mutants, containing the LacZ gene under 15 the control of the LTR promotor of the RSV virus, are then co-transfected into the cells 293 in the presence of the viral DNA from H2d1808 (Weinberg et al., J. Virol. 57 (1986) 633), from which the Z4 region is deleted. According to this second technique, the 20 transcomplementation applies to E4 and no longer to E1. This technique thus makes it possible to generate, as described above, recombinant viruses possessing, as viral gene, only the E4 region.

Example 2

25 This example describes the preparation of defective recombinant adenoviruses according to the invention by co-transfection, with a helper virus, of the DNA of the recombinant virus incorporated into a

plasmid.

For that, a plasmid carrying the joining ITRs of Ad5, the encapsulation sequence, the E4 gene under the control of its own promoter and, as heterologous gene, the LacZ gene under the control of the LTR promoter of the RSV virus was constructed (Figure 4). This plasmid, designated pE4Gal was obtained by cloning and ligation of the following fragments (see Figure 4):

- HindIII-SacII fragment derived from the plasmid pPG144 (Graham et al., EMBO J. 8 (1989) 2077). This fragment carries the ITR sequences from Ad5 in tandem and the encapsulation sequence : HindIII (34920)-SacII (352) fragment;

- fragment from Ad5 between the SacII (localized at the level of the base pair 3827) and PstI (localized at the level of the base pair 4245) sites;

- fragment of pSP 72 (Promega) between the PstI (bp 32) and SalI (bp 34) sites;

- XhoI XbaI fragment of the plasmid pAdLTR GalIX described in Stratford-Perricaudet et al. (JCI 90 (1992) 625). This fragment carries the LacZ gene under the control of the LTR of the RSV virus;

- XbaI (bp 40) - NdeI (bp 2379) fragment of the plasmid pSP 72;

- NdeI (bp 31089) - HindIII (bp 34930) fragment from Ad5. This fragment localized in the right end of the genome of Ad5, contains the E4 region under the control of its own promoter. It was cloned

into the NdeI site (2379) of the plasmid pSP 72 and HindIII site of the first fragment.

This plasmid was obtained by cloning the various fragments into the indicated regions of the plasmid pSP 72. It is understood that equivalent fragments can be obtained by persons skilled in the art from other sources.

The plasmid pE4Gal is then co-transfected with the DNA from the virus H2dl808 into the cells 293 in the presence of calcium phosphate. The recombinant virus is then prepared as described in Example 1. This virus carries, as sole viral gene, the E4 gene from the Ad5 adenovirus (Figure 4). Its genome has a size of about 12 kb, which permits the insertion of heterologous DNA of very large size (up to 20 kb). Thus, persons skilled in the art can easily replace the LacZ gene with any other therapeutic gene such as those mentioned above. Moreover, this virus contains some sequences derived from the plasmid pSP 72, which can be removed by conventional molecular biology techniques if necessary.

Example 3

This example describes the preparation of another defective recombinant adenovirus according to the invention by co-transfection, with a helper virus, of the DNA of the recombinant virus incorporated into a plasmid.

For that, a plasmid carrying the joining ITRs from Ad5, the encapsulation sequence, the E2 gene from Ad2 under the control of its own promoter and, as heterologous gene, the LacZ gene under the control of the LTR promoter of the RSV virus was constructed (Figure 5). This plasmid, designated pE2Gal was obtained by cloning and ligation of the following fragments (see Figure 5):

- HindIII-SacII fragment derived from the plasmid pFG144 (Graham et al., EMBO J.8 (1989) 2077). This fragment carries the ITR sequences from Ad5 in tandem and the encapsulation sequence: HindIII (34920)-SacII (352) fragment. It was cloned, with the following fragment into the HindIII(16)-PstI(32) sites of the plasmid pSP 72;

- fragment from Ad5 between the SacII (localized at the level of the base pair 3827) and PstI (localized at the level of the base pair 4245) sites. This fragment was cloned into the SacII site of the preceding fragment and the PstI (32) site of the plasmid pSP 72;

- fragment of pSP 72 (Promega) between the PstI (bp 32) and SalI (bp 34) sites;

- XhoI-XbaI fragment of the plasmid pAdLTR GalIX described in Stratford-Perricaudet et al. (JCI 90(1992)626). This fragment carries the LacZ gene under the control of the LTR of the RSV virus. It was cloned into the SalI(34) and XbaI sites of the plasmid

pSP 72.

- fragment of pSP 72 (Promega) between the XbaI(bp 34) and BamHI(bp 46) sites;

5 - BamHI(bp 21606). - SmaI(bp 27339) fragment of Ad2. This fragment of the Ad2 genome contains the E2 region under the control of its own promoter. It was cloned into the BamHI(46) and EcoRV sites of the plasmid pSP 72;

10 - EcoRV(bp 81) - HindIII(bp 16) fragment of the plasmid pSP 72.

This plasmid was obtained by cloning the various fragments into the indicated regions of the plasmid pSP 72. It is understood that equivalent fragments can be obtained by persons skilled in the art
15 from other sources.

The plasmid pE2Gal is then co-transfected with the DNA from the H2d1802 virus devoid of the E2 region (Rice et al. J. Virol. 56(1985)767) into the cells 293, in the presence of calcium phosphate. The
20 recombinant virus is then prepared as described in Example 1. This virus carries, as sole viral gene, the E2 gene from the Ad2 adenovirus (Figure 5). Its genome has a size of about 12 kb, which permits the insertion of heterologous DNA of very large size (up to 20 kb).
25 Thus, persons skilled in the art can easily replace the LacZ gene with any other therapeutic gene such as those mentioned above. Moreover, this virus contains some sequences derived from the intermediate plasmid, which

can be removed by conventional molecular biology techniques if necessary.

Example 4

This example describes the construction of complementing cell lines for the E1, E2 and/or E4 regions of adenoviruses. These lines permit the construction of recombinant adenoviruses according to the invention deleted for these regions, without having recourse to a helper virus. These viruses are obtained by in vivo recombination, and may contain major heterologous sequences.

In the cell lines described, the E2 and E4 regions, which are potentially cytotoxic, are placed under the control of an inducible promoter: the LTR of MMTV (Pharmacia) which is induced by dexamethasone, either native or the minimal form described in PNAS 90 (1993) 5603; or the tetracycline-repressible system described by Gossen and Bujard (PNAS 89 (1992) 5547). It is understood that other promoters can be used, and especially LTR variants from MMTV carrying for example heterologous regulatory regions (especially "enhancer" region). The lines of the invention were constructed by transfecting the corresponding cells, in the presence of calcium phosphate, with a DNA fragment carrying the indicated genes (adenovirus regions and/or the gene for the glucocorticoid receptor) under the control of a transcription promoter and a terminator (polyadenylation site). The terminator may be either

the natural terminator of the transfected gene, or a different terminator such as for example the terminator of the early messenger of the SV40 virus.

Advantageously, the DNA fragment also carries a gene
5 permitting the selection of the transformed cells, and for example, the gene for resistance to geneticin. The resistance gene can also be carried by a different DNA fragment, co-transfected with the first.

After transfection, the transformed cells are
10 selected and their DNA is analysed in order to verify the integration of the DNA fragment into the genome.

This technique makes it possible to obtain the following cell lines:

1. Cells 293 possessing the 72K gene of the
15 E2 region of Ad5 under the control of the LTR of MMTV;
2. Cells 293 possessing the gene for the 72K of the E2 region of Ad5 under the control of the LTR of MMTV and the gene for the glucocorticoid receptor;
3. Cells 293 possessing the 72K gene of the
20 E2 region of Ad5 under the control of the LTR of MMTV and the E4 region under the control of the LTR of MMTV;
4. Cells 293 possessing the 72K gene of the E2 region of Ad5 under the control of the LTR of MMTV, the E4 region under the control of the LTR of MMTV and
25 the gene for the glucocorticoid receptor;
5. Cells 293 possessing the E4 region under the control of the LTR of MMTV;
6. Cells 293 possessing the E4 region under

the control of the LTR of MMTV and the gene for the glucorticoid receptor;

7. Cells gm DBP6 possessing the E1A and E1B regions under the control of their own promoter;

5 8. Cells gm DBP6 possessing the E1A and E1B regions under the control of their own promoter and the E4 region under the control of the LTR of MMTV.

Example 5

This example describes the preparation of
10 defective recombinant adenoviruses according to the invention from whose genome the E1, E3 and E4 genes are deleted. According to an advantageous embodiment, illustrated in this example and in Example 3 in particular, the genome of the recombinant adenoviruses
15 of the invention is modified so that at least the E1 and E4 genes are non-functional. Such adenoviruses possess, first of all, a large capacity to incorporate heterologous genes. Moreover, these vectors are highly safe because of the deletion of the E4 region, which is
20 involved in the regulation of the expression of the late genes, in the stability of the late nuclear RNAs, in the extinction of the expression of the proteins of the host cell and in the efficiency of the replication of the viral DNA. These vectors therefore possess a
25 transcriptional background noise and a viral gene expression which are highly reduced. Finally, in a particularly advantageous manner, these vectors can be produced at titres comparable with the wild-type

adenoviruses.

These adenoviruses were prepared from the plasmid pPY55, carrying the modified right part of the genome of the Ad5 adenovirus, either by co-transfection
5 with a helper plasmid (also see Examples 1, 2 and 3), or by means of a complementing line (Example 4).

5.1 Construction of the plasmid pPY55

a) Construction of the plasmid pPY32

The AvrII-BcII fragment of the plasmid
10 pFG144[F.L. Graham et al. EMBO J. 8(1989) 2077-2085], corresponding to the right end of the genome of the Ad5 adenovirus, was first cloned between the XbaI and BamHI sites of the vector pIC19H, prepared from a dam-
context. This generates the plasmid pPY23. One
15 advantageous characteristic of the plasmid pPY23 is that the SalI site obtained from the multiple cloning site of the vector pIC19H remains unique and that it is localized beside the right end of the genome of the Ad5 adenovirus. The HaeIII-SalI fragment of the plasmid
20 pPY23 which contains the right end of the genome of the Ad5 adenovirus, from the HaeIII site localized in position 35614, was then cloned between the EcoRV and XhoI sites of the vector pIC20H, which generates the plasmid pPY29. One advantageous characteristic of this
25 plasmid is that the XbaI and ClaI sites obtained from the multiple cloning site of the vector pIC20H are localized besides the EcoRV/HaeIII junction resulting from the cloning. Furthermore, this junction modifies

the nucleotide context immediately adjacent to the ClaI site which has now become methylable in a dam⁺ context. The XbaI(30470)-MaeII(32811) fragment of the genome of the Ad5 adenovirus was then cloned between the XbaI and
5 ClaI sites of the plasmid pPY29 prepared from a dam⁻ context, which generates the plasmid pPY30. The SstI fragment of the plasmid pPY30, which corresponds to the sequence of the genome of the Ad5 adenovirus from the SstI site in position 30556 up to the right end was
10 finally cloned between the SstI sites of the vector pIC20H, which generates the plasmid pPY31, of which a restriction map of the insert localized between the HindIII sites is given in Figure 6.

The plasmid pPY32 was obtained after partial
15 digestion of the plasmid pPY31 with BglII followed by a total digestion with BamHI, and then religation. The plasmid pPY32 therefore corresponds to the deletion of the genome of the Ad5 adenovirus situated between the BamHI site of the plasmid pPY31 and the BglII site
20 localized in position 30818. A restriction map of the HindIII fragment of the plasmid pPY32 is given in Figure 6. One characteristic of the plasmid pPY32 is that it possesses unique SalI and XbaI sites.

b) Construction of the plasmid pPY47

25 The BamHI(21562)-XbaI(28592) fragment of the genome of the Ad5 adenovirus was first cloned between the BamHI and XbaI sites of the vector pIC19H prepared from a dam⁻ context, which generates the plasmid pPY17.

This plasmid therefore contains a HindIII (26328) - BglII(28133) fragment of the genome of the Ad5 adenovirus, which can be cloned between the HindIII and BglII sites of the vector pIC20R, to generate the
5. plasmid pPY34. One characteristic of this plasmid is that the BamHI site obtained from the multiple cloning site is localized within the immediate vicinity of the HindIII(26328) site of the genome of the Ad5 adenovirus.

10 The BamHI(21562)-HindIII(26328) fragment of the genome of the Ad5 adenovirus obtained from the plasmid pPY17 was then cloned between the BamHI and HindIII sites of the plasmid pPY34 which generates the plasmid pPY39. The BamHI-XbaI fragment of the plasmid
15 pPY39 prepared from a dam- context, containing the part of the genome of the Ad5 adenovirus between the BamHI(21562) and BglII(28133) sites, was then cloned between the BamHI and XbaI sites of the vector pIC19H prepared from a dam- context. This generates the
20 plasmid pPY47 of which one advantageous characteristic is that the SalI site obtained from the multiple cloning site is localized within the vicinity of the HindIII site (Figure 7).

c) Construction of the plasmid pPY55

25 The SalI-XbaI fragment of the plasmid pPY47 prepared from a dam- context, and which contains the part of the genome of the Ad5 adenovirus stretching from the BamHI(21562) site up to the BglII(28133) site,

was cloned between the SalI and XbaI sites of the plasmid pPY32, which generates the plasmid pPY55. This plasmid can be directly used to produce recombinant adenoviruses which are at least deleted for the E3 region (deletion between the BglII sites localized at positions 28133 and 30818 of the genome of the Ad5 adenovirus) and for the entire E4 region (deletion between the MaeII (32811) and HaeIII (35614) sites of the genome of the Ad5 adenovirus (Figure 7)).

5.2 Preparation of the adenoviruses comprising at least one deletion in the E4 region, and preferably at least in the E1 and E4 regions.

a) Preparation by co-transfection with a helper virus E4 into the cells 293

The principle is based on the transcomplementation between a "mini-virus" (helper virus) expressing the E4 region and a recombinant virus deleted at least for E3 and E4. These viruses are obtained either by ligation in vitro, or after recombination in vivo, according to the following strategies:

(i) The DNA from the Ad-dl324 virus (Thimmappaya et al., Cell 31 (1982) 543) and the plasmid pPY55, both digested with BamHI, are first ligated in vitro, and then co-transfected with the plasmid pEAGal (described in Example 2) into the cells 293.

(ii) The DNA from the Ad-dl324 virus digested

with EcoRI and the plasmid pPY55 digested with BamHI are co-transfected, with the plasmid pE4Gal, into the cells 293.

(iii) The DNA from the Ad5 adenovirus and the plasmid pPY55, both digested with BamHI are ligated and then co-transfected with the plasmid pE4Gal into the cells 293.

(iv) The DNA from the Ad5 adenovirus digested with EcoRI and the plasmid pPY55 digested with BamHI are co-transfected with pEAGal into the cells 293.

The strategies (i) and (ii) make it possible to generate a recombinant adenovirus deleted for the E1, E3 and E4 regions; the strategies (iii) and (iv) make it possible to generate a recombinant adenovirus deleted for the E3 and E4 regions. Of course, the DNA from a recombinant virus deleted for the E1 region but expressing any transgene can be used in place of the DNA from the Ad-dl324 virus according to strategies (i) or (ii), with the aim of generating a recombinant virus deleted for the E1, E3 and E4 regions and expressing the said transgene.

b) Preparation by means of cell lines
transcomplementing the E1 and E4
functions

The principle is based here on the fact that a cell line derived from a line expressing the E1 region, for example the line 293, and also expressing at least the open frames ORF6 and ORF6/7 of the E4

region of the Ad5 adenovirus under the control of a promoter, which is for example inducible, is capable of transcomplementing both for the E1 and E4 regions of the Ad5 adenovirus. Such lines were described in
5 Example 4.

A recombinant virus deleted for the E1, E3 and E4 regions can therefore be obtained by ligation in vitro or by recombination in vivo according to the procedures describe above. Regardless of the procedure
10 used for generating the viruses deleted at least for the E4 region, a cytopathic effect (indicating the production of recombinant viruses) was observed after transfection into the cells used. The cells were then harvested, disrupted by three freeze-thaw cycles in
15 their supernatant, and then centrifuged at 4000 rpm for 10 minutes. The supernatant thus obtained was then amplified on a fresh cell culture (cells 293 for the procedures a) and cells 293 expressing the E4 region for the protocol b)). The viruses were then purified
20 from the plaques and their DNA is analysed according to the method of Hirt (previously cited). The virus stocks are then prepared on cesium chloride gradient.

Example 6

This example describes the preparation of
25 defective recombinant adenoviruses according to the invention from whose genome the E1, E3 L5 and E4 genes are deleted. These vectors are particularly advantageous since the L5 region encodes the fibre,

which is an extremely toxic protein for the cell.

These adenoviruses were prepared from the plasmid p2, carrying the modified right part of the genome of the Ad5 adenovirus, by co-transfection with
5 various helper plasmids. They can also be prepared by means of a complementing line.

6.1 Construction of plasmid p2

This plasmid contains all the right region of the genome of the Ad5 adenovirus, from the BamHI(21562)
10 site, from which the fragment between the XbaI(28592) and AvrII(35463) sites, carrying the E3, L5 and E4 genes has been deleted. The plasmid p2 was obtained by cloning and ligating the following fragments into the plasmid pIC19R linearized with BamHI and
15 dephosphorylated (see Figure 8):

- fragment of the genome of the Ad5 adenovirus between the BamHI(21562) and XbaI(28592) sites, and

- right end of the genome of the Ad5
20 adenovirus (containing the right ITR), from the AvrII(35463) site up to the BclI site (BamHI compatible).

6.2. Construction of a helper plasmid (pITRL5-E4) carrying the L5 gene

25 The helper plasmid pITRL5-E4 provides in trans the E4 and L5 genes. It corresponds to the plasmid pE4Gal described in Example 2, containing, in addition, the L5 region encoding the fibre under the

control of the MLP promoter of the Ad2 adenovirus. The plasmid pITRL5-E4 was constructed in the following manner (Figures 9 and 10):

A 58 bp oligonucleotide containing in the 5'-3' direction, a HindIII site, the ATG of the fibre and the coding sequence of the fibre up to the NdeI site in position 31089 of the genome of the Ad5 adenovirus was synthesized. The sequence of this oligonucleotide is given below, in the 5'-3' orientation:

10 AAGCTTATGAGCGCGCAAGACCGTCTGAAGATACCTTCAACCCCGTGTATCCATATG

The HindIII site in 5' and NdeI site in 3', are underlined with a single line, the ATG of the fibre is underlined with a double line.

A SspI-HindIII fragment containing the sequence of the MLP promoter followed by the tripartite leader of the Ad2 adenovirus was isolated from the plasmid pMLP10 (Ballay et al., (1967) UCLA Symposia on molecular and cellular biology, New series, Vol 70, Robinson et al (Eds) New-York, 481). This fragment was inserted with the 58 bp oligonucleotide described above between the NdeI and EcoRV sites of the plasmid pIC19R, to give an intermediate plasmid (see Figure 9). The SacII (rendered blunt)-NdeI fragment of the plasmid pE4Gal (Example 2) was then introduced into the intermediate plasmid between the SspI and NdeI sites in order to generate the plasmid pITRL5-Z4 (Figure 10).

6.3 Preparation of the defective recombinant adenoviruses comprising a deletion in the E1, E3, L5

and E4 regions.

a) Preparation by co-transfection with a helper virus into the cells 293.

The principle is based on the
5 transcomplementation between a "mini-virus" (helper virus) expressing the L5 region or the E4 and L5 regions and a recombinant virus deleted at least for E3, E4 and L5.

These viruses were obtained either by
10 ligation in vitro or after recombination in vivo, according to the following strategies:

(i) The DNA from the Ad-dl324 virus
(Thimmappaya et al., Cell 31 (1982) 543) and the plasmid p2, both digested with BamHI, were first
15 ligated in vitro and then co-transfected with the helper plasmid pITRL5-E4 (Example 6.2.) into the cells 293.

(ii) The DNA from the Ad-dl324 virus digested with EcoRI and the plasmid p2 digested with BamHI are
20 co-transfected with the plasmid pITRL5-E4 into the cells 293.

(iii) The DNA from the Ad5 adenovirus and the plasmid p2, both digested with BamHI, are ligated and then co-transfected with the plasmid pITRL5-E4 into the
25 cells 293.

(iv) The DNA from the Ad5 adenovirus digested with EcoRI and the plasmid p2 digested with BamHI are co-transfected with pITRL5-E4 into the cells 293.

The strategies (i) and (ii) make it possible to generate a recombinant adenovirus deleted for the E1 E3, L5 and E4 regions; the strategies (iii) and (iv) make it possible to generate a recombinant adenovirus
5 deleted for the E3, L5 and E4 regions. Of course, the DNA from a recombinant virus deleted for the E1 region but expressing any transgene can be used in place of the DNA from the Ad-dl324 virus according to strategies (i) or (ii), with the aim of generating a recombinant
10 virus deleted for the E1, E3, L5 and E4 regions and expressing the said transgene.

The procedures described above can also be used with a helper virus carrying only the L5 region, using a cell line capable of expressing the E1 and E4
15 regions of the adenovirus, as described in Example 4.

Moreover, it is also possible to use a complementing line capable of expressing the E1, E4 and L5 regions, so as to completely avoid the use of a helper virus.

20 After the transfection, the viruses produced are recovered, amplified and purified under the conditions described in Example 5.

CLAIMS

1. Defective recombinant adenovirus
comprising:

- the ITR sequences,
- 5 - a sequence permitting the encapsulation,
- a heterologous DNA sequence,

and in which the E1 gene and at least one of the E2, E4
and L1-L5 genes is non-functional.

2. Adenovirus according to Claim 1,
10 characterized in that it is of human, animal or mixed
origin.

3. Adenovirus according to Claim 2,
characterized in that the adenoviruses of human origin
are chosen from those classified in group C, preferably
15 from the type 2 or 5 adenoviruses (Ad2 or Ad5).

4. Adenovirus according to Claim 2,
characterized in that the adenoviruses of animal origin
are chosen from adenoviruses of canine, bovine, murine,
ovine, porcine, avian or simian origin.

20 5. Adenovirus according to one of the
preceding claims, characterized in that at least the E1
and E4 genes are non-functional.

6. Adenovirus according to one of the
preceding claims, characterized in that it is devoid of
25 late genes.

7. Adenovirus according to Claim 1,
characterized in that it comprises:

- the ITR sequences

- a sequence permitting the encapsulation,
- a heterologous DNA sequence, and
- a region carrying the gene or part of the gene E2.

5 8. Adenovirus according to Claim 1,
characterized in that it comprises:

- the ITR sequences,
- a sequence permitting the encapsulation,
- a heterologous DNA sequence, and
- 10 - a region carrying the gene or part of the gene E4.

 9. Adenovirus according to Claim 1,
characterized in that the E1, E3 and E4 genes are
deleted from its genome.

15 10. Adenovirus according to Claim 1,
characterized in that the E1, E3, L5 and E4 genes are
deleted from its genome.

 11. Adenovirus according to one of the
preceding claims, characterized in that it comprises,
20 in addition, a functional gene E3 under the control of
a heterologous promoter.

 12. Adenovirus according to one of the
preceding claims, characterized in that the
heterologous DNA sequence contains one or more
25 therapeutic genes and/or one or more genes encoding
antigenic peptides.

 13. Adenovirus according to Claim 12,
characterized in that the therapeutic gene is chosen

from the genes encoding enzymes, blood derivatives, hormones, lymphokines (interleukins, interferons, TNF and the like), growth factors, neurotransmitters or their precursors or synthetic enzymes, trophic factors (BDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3, NT5 and the like), apolipoproteins (ApoAI, ApoAIV, ApoE and the like), dystrophin or a minidystrophin, tumour suppressor genes or genes encoding factors involved in coagulation (Factors VII, VIII, IX and the like).

10 14. Adenovirus according to Claim 12, characterized in that the therapeutic gene is an antisense gene or sequence whose expression in the target cell makes it possible to control the expression of genes or the transcription of cellular mRNAs.

15 15. Adenovirus according to Claim 12, characterized in that the gene encodes an antigenic peptide capable of generating an immune response in man against microorganisms or viruses.

20 16. Adenovirus according to Claim 15, characterized in that the gene encodes an antigenic peptide specific for the Epstein Barr virus, the HIV virus, the hepatitis B virus, the pseudo-rabies virus or alternatively specific for tumours.

25 17. Adenovirus according to one of the preceding claims, characterized in that the heterologous DNA sequence also comprises sequences permitting the expression of the therapeutic gene and/or of the gene encoding the antigenic peptide in

the infected cell.

18. Adenovirus according to one of the preceding claims, characterized in that the heterologous DNA sequence comprises, upstream of the therapeutic gene, a signal sequence directing the therapeutic product synthesized in the secretory pathways of the target cell.

19. Cell line infectible by an adenovirus comprising, integrated into its genome, the functions necessary for the complementation of a defective recombinant adenovirus according to one of Claims 1 to 18.

20. Cell line according to Claim 19, characterized in that it contains, in its genome, at least the E1 and E2 genes from an adenovirus.

21. Cell line according to Claim 20, characterized in that it contains, in addition, the E4 gene from an adenovirus.

22. Cell line according to Claim 19, characterized in that it contains, in its genome, at least the E1 and E4 genes from an adenovirus.

23. Cell line according to Claims 19 to 22, characterized in that it contains, in addition, the gene for the glucocorticoid receptor.

24. Cell line according to Claims 19 to 23, characterized in that the E2 and E4 genes are placed under the control of an inducible promoter.

25. Cell line according to Claim 24,

characterized in that the inducible promoter is the LTR promoter of MMTV.

26. Cell line according to Claims 19 to 25,
characterized in that the E2 gene encodes the 72K
5 protein.

27. Cell line according to Claims 19 to 26,
characterized in that it is obtained from the line 293.

28. Pharmaceutical composition comprising at
least one defective recombinant adenovirus according to
10 one of Claims 1 to 18.

29. Pharmaceutical composition according to
Claim 28, comprising a recombinant adenovirus according
to one of Claims 5 to 10.

30. Pharmaceutical composition according to
15 Claims 28 or 29, comprising a vehicle pharmaceutically
acceptable for an injectable formulation.




Figure 1

2 / 9




Figure 2





Figure 3



X

H2dl808





Figure 4

REPLACEMENT SHEET (RULE 26)



X

H2dl802




Figure 5

REPLACEMENT SHEET (RULE 26)




Figure 6

REPLACEMENT SHEET (RULE 26)




Figure 7




Figure 8

oligo containing ATG of the fibre




Figure 9




Figure 10

INTERNATIONAL SEARCH REPORT

Intern. Application No.
PCT/FR 94/00851

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/86 C12N15/34 C12N5/10 C12N7/04 C07K14/075

According to International Patent Classification (IPC) or to both national classification and IPC

8. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO, A, 94 12649 (GENZYME CORP.) 9 June 1994 see the whole document ----	1-3, 5, 7, 9, 19, 28-30
A	JOURNAL OF VIROLOGY vol. 63, no. 6, June 1989 pages 2709 - 2717 BARISS, L.E. 'The cellular transcription factor E2f requires viral E1A and E4 gene products for increased DNA-binding activity and functions to stimulate adenovirus E2A gene expression' see page 2715, column 2, line 53 - line 62 ----- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

5 September 1994

Date of mailing of the international search report

21-09-1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2220 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Chambonnet, F

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HUMAN GENE TRANSFER vol. 219 , 1991 pages 51 - 61 STATFORD-PERRICAUDET, L. & PERRICAUDET, M. 'Gene transfer into animals: the promise of adenovirus' see page 58, paragraph 6 ---	1
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 80 , September 1983 , WASHINGTON US pages 5383 - 5386 WEINBERG, D.H. & KETNER, G. 'A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2' see the whole document ---	21
A	NUCLEIC ACIDS RESEARCH. vol. 17, no. 8 , 1989 , ARLINGTON, VIRGINIA US pages 3037 - 3047 KETNER, G. ET AL. 'Complementation of adenovirus E4 mutants by transient expression of E4 cDNA and deletion plasmids' ---	21
A	WO,A,93 06223 (CNRS) 1 April 1993 see the whole document -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/FR 94/00851

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9412649	09-06-94	AU-B- 5734994	22-06-94
WO-A-9406223	01-04-93	FR-A- 2681786	02-04-93
		AU-A- 2790292	27-04-93
		EP-A- 0559884	15-09-93
		JP-T- 6502771	31-03-94

A. CLASSEMENT DE L'OBJET DE LA DEMANDE

CIB 6 C12N15/86 C12N15/34 C12N5/10 C12N7/04 C07K14/075

Selon la classification internationale des brevets (CIB) ou à la fois selon la classification nationale et la CIB

B. DOMAINES SUR LESQUELS LA RECHERCHE A PORTE

Documentation minimale consultée (système de classification suivi des symboles de classement)

CIB 6 C12N C07K A61K

Documentation consultée autre que la documentation minimale dans la mesure où ces documents relèvent des domaines sur lesquels a porté la recherche

Bases de données électronique consultée au cours de la recherche internationale (nom de la base de données, et si cela est raisonnable, termes de recherche utilisés)

C. DOCUMENTS CONSIDERES COMME PERTINENTS

Catégorie	Identification des documents cités, avec, le cas échéant, l'indication des passages pertinents	no. des revendications visées
P, X	WO, A, 94 12649 (GENZYME CORP.) 9 Juin 1994 voir le document en entier ---	1-3, 5, 7, 9, 19, 28-30
A	JOURNAL OF VIROLOGY vol. 63, no. 6, Juin 1989 pages 2709 - 2717 BABISS, L.E. 'The cellular transcription factor E2f requires viral E1A and E4 gene products for increased DNA-binding activity and functions to stimulate adenovirus E2A gene expression' voir page 2715, colonne 2, ligne 53 - ligne 62 --- -/--	1

☒ Voir la suite du cadre C pour la fin de la liste des documents☒ Les documents de familles de brevets sont indiqués en abrégé

* Catégories spéciales de documents cités

- * A* document définissant l'état général de la technique, non considéré comme particulièrement pertinent
- * E* document antérieur, mais publié à la date de dépôt international ou après cette date
- * L* document pouvant prêter un doute sur une revendication de priorité ou cité pour déterminer la date de publication d'une autre citation ou pour une raison spéciale (telle qu'indiquée)
- * T* document se référant à une divulgation orale, à un usage, à une exposition ou tous autres moyens
- * I* document publié avant la date de dépôt international, mais postérieurement à la date de priorité revendiquée

T* document ultérieur publié après la date de dépôt international ou la date de priorité et n'appartenant pas à l'état de la technique pertinent, mais cité pour comprendre le principe ou la théorie constituant la base de l'invention

X* document particulièrement pertinent: l'invention revendiquée ne peut être considérée comme nouvelle ou comme impliquant une activité inventive par rapport au document considéré isolément

Y* document particulièrement pertinent: l'invention revendiquée ne peut être considérée comme impliquant une activité inventive lorsque le document est associé à un ou plusieurs autres documents de même nature, cette combinaison étant évidente pour une personne du métier

A* document qui fait partie de la même famille de brevets

Date à laquelle la recherche internationale a été effectivement achevée

5 Septembre 1994

Date d'expédition du présent rapport de recherche internationale

21-09-1994

Nom et adresse postale de l'administration chargée de la recherche internationale

Office Européen des Brevets, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tél. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Fonctionnaire autorisé

Chambonnet, F

C. (suite) DOCUMENTS CONSIDERES COMME PERTINENTS

Catégorie	Identification des documents cités, avec, le cas échéant, l'indication des passages pertinents	no. des revendications visées
A	<p>HUMAN GENE TRANSFER vol. 219 , 1991 pages 51 - 61 STATFORD-PERRICAUDET, L. & PERRICAUDET, M. 'Gene transfer into animals: the promise of adenovirus' voir page 58. alinéa 6</p>	1
A	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 80 , Septembre 1983 , WASHINGTON US pages 5383 - 5386 WEINBERG, D.H. & KETNER, G. 'A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2' voir le document en entier</p>	21
A	<p>NUCLEIC ACIDS RESEARCH. vol. 17, no. 8 , 1989 , ARLINGTON, VIRGINIA US pages 3037 - 3047 KETNER, G. ET AL. 'Complementation of adenovirus E4 mutants by transient expression of E4 cDNA and deletion plasmids'</p>	21
A	<p>WO,A,93 06223 (CNRS) 1 Avril 1993 voir le document en entier</p>	1

RAPPORT DE RECHERCHE INTERNATIONALE

Renseignements relatifs aux familles de brevets

Demande internationale No

PCT/FR 94/00851

Document brevet cité au rapport de recherche	Date de publication	Membre(s) de la famille de brevet(s)	Date de publication
WO-A-9412649	09-06-94	AU-B- 5734994	22-06-94
WO-A-9306223	01-04-93	FR-A- 2681786	02-04-93
		AU-A- 2790292	27-04-93
		EP-A- 0559884	15-09-93
		JP-T- 6502771	31-03-94